Finance

Lists
Outlook: 6.2% bullish·81.2% bearish
Go to analysis
ZURA:NASDAQ
Zura Bio Ltd
1,24 USD
0,00%
(0,00) 1D
1,19 USD
-4,43% (-0,055)
After hours
Closed: 13-ноя., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZURA...
Open
1,24 USD
High
1,25 USD
Low
1,13 USD
Mkt. cap
119,44 млн
Avg. vol.
6,94 млн
Volume
4,25 млн
52-wk high
7,44 USD
52-wk low
0,93 USD
EPS
-1,11 USD
Beta
0,03
Shares outstanding
96,32 млн
No. of employees
40
Open
1,24 USD
High
1,25 USD
Low
1,13 USD
Mkt. cap
119,44 млн
Avg. vol.
6,94 млн
Volume
4,25 млн
52-wk high
7,44 USD
52-wk low
0,93 USD
EPS
-1,11 USD
Beta
0,03
Shares outstanding
96,32 млн
No. of employees
40
News stories
From web sources and news partners
About Zura Bio Ltd
CEO-
Employees40
Founded2022
Headquarters-
SectorHealth Care
Industry-
Websitezurabio.com
Analyst ratings
Based on 6 analysts giving stock ratings to ZURA in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ZURA in the last 3 months.
Highest
Current 1,24 USD
26,00 USD (+1 996,77%)
Average
10,67 USD (+760,48%)
Lowest
5,00 USD (+303,23%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kaveri Pohlman
Clear Street
Buy
Maintained
10,00 USD
+706,5%
11/10/2026
Justin Kim
Oppenheimer
Buy
Maintained
5,00 USD
+303,2%
11/10/2026
Yatin Suneja
Guggenheim
Buy
Maintained
8,00 USD
+545,2%
11/10/2026
Thomas Smith
Leerink Partners
Buy
Maintained
5,00 USD
+303,2%
11/09/2026
Martin Fan
Wedbush
Buy
Reiterated
10,00 USD
+706,5%
11/09/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
26,00 USD
+1 996,8%
10/07/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
11,00 USD
+787,1%
10/02/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
20,00 USD
+1 512,9%
10/02/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
08/11/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
11,00 USD
+787,1%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10,96 млн
14,75 млн
20,71 млн
19,49 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,46 млн
10,75 млн
8,62 млн
9,28 млн
Operating expense
18,41 млн
25,50 млн
29,32 млн
28,77 млн
Total operating expenses
18,41 млн
25,50 млн
29,32 млн
28,77 млн
Operating income
-18,41 млн
-25,50 млн
-29,32 млн
-28,77 млн
Other non operating income
-40,00 миң
-43,00 миң
1,02 млн
-32,00 миң
EBT including unusual items
-17,18 млн
-24,22 млн
-26,38 млн
-27,05 млн
EBT excluding unusual items
-17,18 млн
-24,22 млн
-26,38 млн
-27,05 млн
Income tax expense
-
-
-81,00 миң
-1,22 млн
Effective tax rate
-
-
0,31%
4,51%
Other operating expenses
-
-
-
-
Net income
-17,18 млн
-24,22 млн
-26,30 млн
-25,82 млн
Net profit margin
-
-
-
-
Earnings per share
-0,49
-0,22
-0,21
-0,20
Interest and investment income
1,28 млн
1,32 млн
1,92 млн
1,76 млн
Interest expense
-
-
-
-
Net interest expenses
1,28 млн
1,32 млн
1,92 млн
1,76 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,40 млн
-25,48 млн
-29,30 млн
-28,75 млн
Gain or loss from assets sale
-
3,00 миң
2,00 миң
1,00 миң
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору